3-aminocyclopentane carboxamide derivatives

Patent metadata

Field	Value
Publication number	US-9732032-B2
Application number	US-201314442242-A
Country	US
Kind code	B2
Filing date	Oct 17, 2013
Priority date	Nov 16, 2012
Publication date	Aug 15, 2017
Grant date	Aug 15, 2017

Abstract

Compounds of the formula I

in which R 1 , R 4 , R, X 1 , X 2 , X 3 , X 4 , q and W have the meanings indicated in Claim 1 , are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

First claim

The invention claimed is:

1. A compound of the formula

No.
Name

“A1”
4-(1,3-benzoxazol-2-yl)-N-[(1R,3S)-3-

(ethylcarbamoyl)cyclopentyl]-N-methyl-benzamide

“A2”
N-((1R,3S)-3-ethylcarbamoyl-cyclopentyl)-N-methyl-4-(1-methyl-

1H-benzoimidazol-2-yl)-benzamide

“A3”
4-benzothiazol-2-yl-N-((1R,3S)-3-ethylcarbamoyl-cyclopentyl)-

N-methyl-benzamide

“A4”
4′-[(R)-(tetrahydro-furan-3-yl)oxy]-biphenyl-4-carboxylic acid

((1R,3S)-3-ethylcarbamoyl-cyclopentyl)-methyl-amide

“A5”
4-benzoxazol-2-yl-N-((1R,3S)-3-isopropylcarbamoyl-

cyclopentyl)-N-methyl-benzamide

“A6”
4-benzoxazol-2-yl-N-((1R,3S)-3-cyclopropylcarbamoyl-

cyclopentyl)-N-methyl-benzamide

“A7”
4-benzoxazol-2-yl-N-((1R,3S)-3-cyclopentylcarbamoyl-

cyclopentyl)-N-methyl-benzamide

“A8”
4-benzoxazol-2-yl-N-((1R,3S)-3-(cyclohexylmethyl-carbamoyl)-

cyclopentyl]-N-methyl-benzamide

“A9”
4-benzoxazol-2-yl-N-methyl-N-[(1R,3S)-3-(pyrrolidine-1-

carbonyl)-cyclopentyl]-benzamide

“A10”
4-(1,3-benzoxazol-2-yl)-N-[(1S,3R)-3-

(ethylcarbamoyl)cyclopentyl]-N-methyl-benzamide

“A11”
4-(1H-benzimidazol-2-yl)-N-[(1R,3S)-3-

(ethylcarbamoyl)cyclopentyl]-N-methyl-benzamide

“A12”
4-benzoxazol-2-yl-N-ethyl-N-((1R,3S)-3-ethylcarbamoyl-

cyclopentyl)-benzamide

“A13”
4-benzoxazol-2-yl-N-benzyl-N-((1R,3S)-3-ethylcarbamoyl-

cyclopentyl)-benzamide

“A14”
N-((1R,3S)-3-ethylcarbamoyl-cyclopentyl)-N-methyl-4-

oxazolo[5,4-b]pyridin-2-yl-benzamide

“A15”
N-((1R,3S)-3-ethylcarbamoyl-cyclopentyl)-N-methyl-4-

oxazolo[5,4-c]pyridin-2-yl-benzamide

“A16”
4′-methoxy-biphenyl-4-carboxylic acid ((1R,3S)-3-

ethylcarbamoyl-cyclopentyl)-methyl-amide

“A17”
4′-[(S)-(tetrahydro-furan-3-yl)oxy]-biphenyl-4-carboxylic acid

((1R,3S)-3-ethylcarbamoyl-cyclopentyl)-methyl-amide

“A18”
4-benzoxazol-2-yl-N-((1R,3S)-3-ethylcarbamoyl-cyclopentyl)-2-

fluoro-N-methyl-benzamide

“A19”
N-((1R,3S)-3-ethylcarbamoyl-cyclopentyl)-4-(5-fluoro-

benzoxazol-2-yl)-N-methyl-benzamide

“A20”
4-benzoxazol-2-yl-N-((1R,3S)-3-ethylcarbamoyl-cyclopentyl)-

2,6-difluoro-N-methyl-benzamide

“A21”
N-((1R,3S)-3-ethylcarbamoyl-cyclopentyl)-N-methyl-4-(5-

trifluoromethoxy-benzoxazol-2-yl)-benzamide

“A22”
4-benzoxazol-2-yl-N-((1R,3S)-3-ethylcarbamoyl-cyclopentyl)-N-

methyl-3-trifluoromethyl-benzamide

“A23”
4-(6-chloro-benzoxazol-2-yl)-N-((1R,3S)-3-ethylcarbamoyl-

cyclopentyl)-N-methyl-benzamide

“A24”
N-((1R,3S)-3-ethylcarbamoyl-cyclopentyl)-N-methyl-4-

naphthalen-2-yl-benzamide

“A25”
N-((1R,3S)-3-Ethylcarbamoyl-cyclopentyl)-4-isoquinolin-6-yl-N-

methyl-benzamide

“A26”
4-benzofuran-5-yl-N-((1R,3S)-3-ethylcarbamoyl-cyclopentyl)-N-

methyl-benzamide

“A27”
N-((1R,3S)-3-ethylcarbamoyl-cyclopentyl)-N-methyl-4-(1-

methyl-1H-benzoimidazol-5-yl)-benzamide

“A28”
4-benzoxazol-2-yl-N-[(1R,3S)-3-(4-ethyl-piperazine-1-carbonyl)-

cyclopentyl]-N-methyl-benzamide

“A29”
4-benzoxazol-2-yl-N-cyclopropylmethyl-N-((1R,3S)-3-

ethylcarbamoyl-cyclopentyl)-benzamide

“A30”
N-((1R,3S)-3-ethylcarbamoyl-cyclopentyl)-4-(1H-indol-2-yl)-N-

methyl-benzamide

“A31”
N-((1R,3S)-3-ethylcarbamoyl-cyclopentyl)-N-methyl-4-[5-

(pyrrolidine-1-carbonyl)-benzoxazol-2-yl]-benzamide

“A32”
4-benzoxazol-2-yl-N-[(1R,3S)-3-(cyclopentylmethyl-carbamoyl)-

cyclopentyl]-N-methyl-benzamide

“A33”
4-benzoxazol-2-yl-N-methyl-N-[(1R,3S)-3-(oxetan-3-

ylcarbamoyl)-cyclopentyl]-benzamide

“A34”
4-benzoxazol-2-yl-N-methyl-N-((1R,3S)-3-{[(S)-1-(tetrahydro-

furan-2-yl)methyl]-carbamoyl}-cyclopentyl)-benzamide

“A35”
4-benzoxazol-2-yl-N-methyl-N-((1R,3S)-3-{[(R)-1-(tetrahydro-

furan-2-yl)methyl]-carbamoyl}-cyclopentyl)-benzamide

“A36”
4-benzoxazol-2-yl-N-[(1R,3S)-3-(2-methoxy-ethylcarbamoyl)-

Assignees

• Merck Patent Gmbh

Inventors

• Tsaklakidis Christos
• Staehle Wolfgang
• Leuthner Brigitta
• Czodrowski Paul

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title